Benzinga - by Benzinga Insights, Benzinga Staff Writer.
In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Agilent Technologies (NYSE:A) against its key competitors in the Life Sciences Tools & Services industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
Agilent Technologies Background Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
| Agilent Technologies Inc | 31.52 | 6.25 | 5.94 | 4.97% | $0.46 | $0.86 | -8.39% |
| Thermo Fisher Scientific Inc | 37.30 | 4.88 | 5.30 | 2.88% | $2.79 | $4.21 | -3.41% |
| Danaher Corp | 48.56 | 3.67 | 8.32 | 2.04% | $1.92 | $3.49 | -2.57% |
| IQVIA Holdings Inc | 29.48 | 6.20 | 2.65 | 4.62% | $0.77 | $1.29 | 2.33% |
| West Pharmaceutical Services Inc | 42.20 | 8.69 | 8.19 | 4.15% | $0.16 | $0.23 | -2.96% |
| Waters Corp | 29.61 | 14.23 | 6.15 | 8.49% | $0.18 | $0.38 | -22.29% |
| Avantor Inc | 61.76 | 2.99 | 2.32 | 1.14% | $0.24 | $0.57 | -5.65% |
| Revvity Inc | 74.35 | 1.72 | 4.98 | 0.33% | $0.17 | $0.36 | -3.7% |
| Medpace Holdings Inc | 41.35 | 18.71 | 6.57 | 16.67% | $0.11 | $0.16 | 17.73% |
| Bio-Techne Corp | 61.66 | 6.03 | 10.76 | 2.47% | $0.09 | $0.2 | 3.16% |
| Charles River Laboratories International Inc | 25.21 | 3.04 | 2.69 | 1.86% | $0.22 | $0.34 | -1.73% |
| Bruker Corp | 23.80 | 6.95 | 3.18 | 3.65% | $0.11 | $0.35 | 5.31% |
| Repligen Corp | 522.52 | 4 | 13.06 | 0.11% | $0.02 | $0.07 | -17.14% |
| Stevanato Group SPA | 33.57 | 3.51 | 4.19 | 1.53% | $0.05 | $0.06 | -0.84% |
| Sotera Health Co | 62.89 | 7.88 | 3.15 | 1.44% | $0.09 | $0.13 | 12.51% |
| Average | 78.16 | 6.61 | 5.82 | 3.67% | $0.49 | $0.85 | -1.38% |
th, td { padding: 8px; text-align: left; }
th { background-color: #293a5a; color: #fff; text-align: left; }
tr:nth-child(even) { background-color: #f2f4f8; }
tr:hover { background-color: #e1e4ea; }
td:nth-child(3), td:nth-child(5) { text-align: left; }
.dividend-amount { font-weight: bold; color: #0d6efd; }
.dividend-frequency { font-size: 12px; color: #6c757d; } By thoroughly analyzing Agilent Technologies, we can discern the following trends:
- The stock's Price to Earnings ratio of 31.52 is lower than the industry average by 0.4x, suggesting potential value in the eyes of market participants.
- Considering a Price to Book ratio of 6.25, which is well below the industry average by 0.95x, the stock may be undervalued based on its book value compared to its peers.
- The stock's relatively high Price to Sales ratio of 5.94, surpassing the industry average by 1.02x, may indicate an aspect of overvaluation in terms of sales performance.
- The Return on Equity (ROE) of 4.97% is 1.3% above the industry average, highlighting efficient use of equity to generate profits.
- With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $460 Million, which is 0.94x below the industry average, the company may face lower profitability or financial challenges.
- With higher gross profit of $860 Million, which indicates 1.01x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
-
The company is witnessing a substantial decline in revenue growth, with a rate of -8.39% compared to the industry average of -1.38%, which indicates a challenging sales environment.
The debt-to-equity (D/E) ratio measures the financial leverage of a company by evaluating its debt relative to its equity.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By analyzing Agilent Technologies in relation to its top 4 peers based on the Debt-to-Equity ratio, the following insights can be derived:
- Compared to its top 4 peers, Agilent Technologies has a stronger financial position indicated by its lower debt-to-equity ratio of 0.41.
- This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.